Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR2 |
Variant | L33S |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 L33S lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). L33S results in decreased proliferation in a competition assay but transformation activity similar to wild-type Fgfr2 in cultured cells (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 L33S |
Transcript | NM_000141.5 |
gDNA | chr10:g.121593720A>G |
cDNA | c.98T>C |
Protein | p.L33S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144919.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144915.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144915.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144918.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144918.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144916.1 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
NM_001144916.2 | chr10:g.121593720A>G | c.98T>C | p.L33S | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 L33S | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 L33S | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 L33S were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |